{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:01:43Z","timestamp":1780322503855,"version":"3.54.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"DOI":"10.1093\/jmcb\/mjac039","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T16:43:33Z","timestamp":1656348213000},"source":"Crossref","is-referenced-by-count":16,"title":["Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way"],"prefix":"10.1093","volume":"14","author":[{"given":"Ot\u00e1vio Augusto","family":"Chaves","sequence":"first","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"},{"name":"National Institute for Science and Technology on Innovation on Neglected Diseases (INCT\/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Q","family":"Sacramento","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"},{"name":"National Institute for Science and Technology on Innovation on Neglected Diseases (INCT\/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fintelman-Rodrigues","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"},{"name":"National Institute for Science and Technology on Innovation on Neglected Diseases (INCT\/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8092-2149","authenticated-orcid":false,"given":"Jairo Ramos","family":"Temerozo","sequence":"additional","affiliation":[{"name":"National Institute for Science and Technology on Neuroimmunomodulation (INCT\/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"},{"name":"Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-2876","authenticated-orcid":false,"given":"Filipe","family":"Pereira-Dutra","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella M","family":"Mizurini","sequence":"additional","affiliation":[{"name":"Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro (UFRJ) , Rio de Janeiro, RJ , 21941-590,\u00a0 Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson Q","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro (UFRJ) , Rio de Janeiro, RJ , 21941-590,\u00a0 Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"},{"name":"National Institute for Science and Technology on Innovation on Neglected Diseases (INCT\/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T","family":"Bozza","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo Caire","family":"Castro-Faria-Neto","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago Moreno L","family":"Souza","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"},{"name":"National Institute for Science and Technology on Innovation on Neglected Diseases (INCT\/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"2022122008593889500_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"Adam","year":"2021","journal-title":"Blood Adv."},{"key":"2022122008593889500_bib2","doi-asserted-by":"crossref","first-page":"e200179","DOI":"10.1590\/0074-02760200179","article-title":"Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach","volume":"115","author":"Biembengut","year":"2020","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"2022122008593889500_bib3","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"2022122008593889500_bib4","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMclde2028217","article-title":"Anticoagulation in hospitalized patients with Covid-19","volume":"383","author":"Chowdhury","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2022122008593889500_bib5","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","article-title":"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study","volume":"1","author":"Chu","year":"2020","journal-title":"Lancet Microbe"},{"key":"2022122008593889500_bib6","doi-asserted-by":"crossref","first-page":"23544","DOI":"10.1002\/anie.202010316","article-title":"Allosteric inhibition of the SARS-CoV-2 main protease\u2014insights from mass spectrometry-based assays","volume":"59","author":"El-Baba","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"2022122008593889500_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13318-011-0037-x","article-title":"Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor","volume":"36","author":"He","year":"2011","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"2022122008593889500_bib8","doi-asserted-by":"crossref","first-page":"e0262482","DOI":"10.1371\/journal.pone.0262482","article-title":"Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease","volume":"17","author":"Papaj","year":"2022","journal-title":"PLoS One"},{"key":"2022122008593889500_bib9","doi-asserted-by":"crossref","first-page":"n311","DOI":"10.1136\/bmj.n311","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study","volume":"372","author":"Rentsch","year":"2021","journal-title":"BMJ"},{"key":"2022122008593889500_bib10","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1055\/s-0040-1720962","article-title":"Safety and efficacy of apixaban for therapeutic anticoagulation in critically Ill ICU patients with severe COVID-19 respiratory disease","volume":"4","author":"Wenzler","year":"2020","journal-title":"TH Open"}],"container-title":["Journal of Molecular Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jmcb\/advance-article-pdf\/doi\/10.1093\/jmcb\/mjac039\/44266695\/mjac039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jmcb\/article-pdf\/14\/6\/mjac039\/48247045\/mjac039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jmcb\/article-pdf\/14\/6\/mjac039\/48247045\/mjac039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T09:01:02Z","timestamp":1671526862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jmcb\/article\/doi\/10.1093\/jmcb\/mjac039\/6618655"}},"subtitle":[],"editor":[{"given":"Jiarui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jmcb\/mjac039","relation":{},"ISSN":["1674-2788","1759-4685"],"issn-type":[{"value":"1674-2788","type":"print"},{"value":"1759-4685","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,6]]},"article-number":"mjac039"}}